GLP-1 Medications Explained: Beyond Weight Loss

By Courtney A. Washington, DO

What Is GLP-1?

GLP-1 stands for Glucagon-Like Peptide-1, a hormone naturally produced in the intestines after eating.

Its job is to help regulate:

• Appetite
• Blood sugar levels
• Insulin release
• Digestion
• Satiety, or the feeling of fullness

Think of GLP-1 as one of the body’s natural metabolic messengers. When we eat, GLP-1 signals the brain that we have had enough food, slows stomach emptying, and helps the pancreas release insulin appropriately.

The challenge is that natural GLP-1 breaks down quickly. GLP-1 receptor agonists are medications designed to mimic this hormone but last much longer in the body.

How Do GLP-1 Medications Work?

1. They Reduce Hunger Signals

GLP-1 receptors are found in areas of the brain involved in appetite regulation. Many patients describe feeling satisfied with smaller portions, having fewer cravings, and experiencing less “food noise.”

That last point is important. Many people do not realize how much mental energy they spend thinking about food until that constant noise quiets down.

2. They Slow Gastric Emptying

GLP-1 medications slow how quickly food leaves the stomach. This helps patients feel full sooner and stay full longer.

This mechanism can also help reduce blood sugar spikes after meals, but it is also one reason some patients may experience nausea, bloating, reflux, or constipation.

3. They Improve Blood Sugar Regulation

These medications help the body release insulin when needed and reduce excess glucagon production. This is why GLP-1 medications were originally developed for Type 2 Diabetes.

4. Some Newer Medications Target Multiple Hormones

Tirzepatide, sold under brand names including Mounjaro® and Zepbound®, works on both GLP-1 and GIP receptors. By targeting more than one hormone pathway, these medications may produce greater weight loss and metabolic improvement in some patients.

Obesity Is More Than Calories

One of the biggest misconceptions in healthcare is that obesity is simply about willpower.

The science tells a different story. Obesity is influenced by:

• Genetics
• Hormones
• Sleep
• Stress
• Medications
• Insulin resistance
• Chronic inflammation
• Environmental factors

This is why two people can eat similar diets and exercise similarly yet have very different metabolic outcomes.

The Cardiovascular Benefits: The Bigger Story

While weight loss receives most of the media attention, cardiovascular protection may ultimately be one of the most important benefits of GLP-1 therapy.

Many patients with obesity also have high blood pressure, prediabetes, diabetes, elevated cholesterol, sleep apnea, fatty liver disease, or chronic inflammation. These conditions increase the risk of heart attack, stroke, and premature death.

The SELECT Trial, published in The New England Journal of Medicine, showed that semaglutide reduced major cardiovascular events in adults with overweight or obesity and established cardiovascular disease, even in patients without diabetes.

The Connection Between Obesity and Inflammation

One topic I discuss often is inflammation.

Fat tissue is not just storage. It is metabolically active tissue that can release inflammatory chemicals. Over time, chronic inflammation contributes to insulin resistance, cardiovascular disease, fatty liver disease, joint pain, and other chronic conditions.

Emerging research suggests GLP-1 medications may help reduce inflammatory markers. While we still need more data, this may help explain why some patients experience improvements beyond weight loss alone.

Emerging Research: Addiction and Reward Pathways

One of the most fascinating areas of current research involves addiction and reward pathways in the brain.

GLP-1 receptors are present in areas of the brain involved in reward, cravings, and impulse control. Early studies suggest these medications may influence cravings related to alcohol, nicotine, opioids, and compulsive eating behaviors.

Some patients report less interest in alcohol, fewer binge-eating episodes, and decreased impulsive behaviors around food.

At this time, GLP-1 medications are not standard addiction treatments. However, the research is promising and reminds us that metabolism, brain chemistry, cravings, and behavior are deeply connected.

Could GLP-1 Medications Impact Brain Health?

Researchers are also studying whether GLP-1 therapies may have neuroprotective effects.

Potential areas of investigation include:

• Alzheimer’s disease
• Parkinson’s disease
• Cognitive decline
• Neuroinflammation

These uses are still experimental, but the research supports a bigger idea: metabolic health and brain health are connected.

What Patients Should Know Before Starting

Lifestyle Still Matters

GLP-1 medications are powerful tools, but they are not magic. The best outcomes occur when medication is combined with nutrition, movement, strength training, sleep optimization, stress management, and regular medical follow-up.

Muscle Preservation Is Critical

Rapid weight loss can lead to muscle loss. Patients should prioritize protein intake, resistance training, and monitoring body composition when possible.

Side Effects Can Occur

Common side effects include nausea, constipation, diarrhea, bloating, reflux, and decreased appetite. These symptoms often improve with gradual dose escalation and appropriate nutrition adjustments.

These Medications Are Not for Everyone

Patients should review their full medical history with a qualified healthcare professional before starting. Certain conditions, medication interactions, pregnancy considerations, gastrointestinal disorders, and personal or family history may affect whether these medications are appropriate.

The Future of Metabolic Medicine

We are entering a new era in medicine.

For too long, obesity was viewed as a lifestyle issue. Today, we recognize it as a complex chronic disease involving hormones, genetics, inflammation, cardiovascular risk, and brain signaling pathways.

GLP-1 medications have helped shift that conversation.

For many patients, these medications are not simply helping them lose weight. They are helping improve metabolic health, reduce cardiovascular risk, decrease inflammation, and potentially prevent future disease.

And that may ultimately be their greatest impact.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221-2232.
4. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740-756.
5. Holst JJ. The Physiology of Glucagon-Like Peptide 1. Physiological Reviews. 2007;87(4):1409-1439.
6. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. Updated annually.
7. National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight and Obesity.
8. National Heart, Lung, and Blood Institute. Overweight and Obesity: Health Consequences and Treatment Approaches.
9. Jensterle M, Rizzo M, Haluzík M, Janež A. Evolving Role of GLP-1 Receptor Agonists Beyond Glycemic Control. Metabolism. 2024.
10. Sweeney P, Halberstadt J, et al. GLP-1 Receptor Agonists and Addiction-Related Behaviors: Emerging Evidence and Future Directions. Frontiers in Neuroscience. 2024.

Disclaimer: This article is for educational purposes only and does not replace personalized medical advice. Always speak with your healthcare provider before starting, stopping, or changing any medication.